Literature DB >> 7200405

Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography.

M E Bertrand, J M LaBlanche, P Y Tilmant, F A Thieuleux, M R Delforge, A G Carre, P Asseman, B Berzin, C Libersa, J M Laurent.   

Abstract

We established the incidence of coronary artery spasm provoked by 0.4 mg of methergine in 1089 consecutive patients undergoing coronary angiography. The test was performed after routine coronary arteriography. Subjects included patients with angina, both typical and atypical, patients who had recently had myocardial infarction and patients with either valvular disease or congestive cardiomyopathy. Patients with spontaneous spasm, left main narrowing or severe three-vessel disease were excluded. One hundred thirty-four patients experienced focal spasm. Focal spasm was uncommon in patients with atypical precordial pain (1.2%), angina of effort (4.3%), valvular disease (1.95%) or cardiomyopathy (0%). It occurred most often in patients with angina at rest and less often in patients with angina both at rest and induced by exercise. Spasm was provoked in 20% of patients with recent transmural infarction, but in only 6.2% of patients studied later after infarction. Spasm was superimposed on fixed atherosclerotic lesions in 60% of the patients. No serious complications were encountered. Although the patients who underwent provocation tests in this study are not representative of all patients with coronary artery disease, spasm occurred in 20% of patients who experienced a coronary event and in 15% of patients who complained of chest pain.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7200405     DOI: 10.1161/01.cir.65.7.1299

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  59 in total

1.  Coronary Artery Spasm.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-02

2.  Safety and optimal protocol of provocation test for diagnosis of multivessel coronary spasm.

Authors:  Shozo Sueda; Toru Miyoshi; Yasuhiro Sasaki; Tomoki Sakaue; Hirokazu Habara; Hiroaki Kohno
Journal:  Heart Vessels       Date:  2014-11-01       Impact factor: 2.037

3.  Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction.

Authors:  S J MacLennan; G R Martin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

4.  Urgent surgical reperfusion for intraoperative myocardial infarction following coronary artery bypass grafting.

Authors:  Y Niimi; K Kaya
Journal:  J Anesth       Date:  1991-07       Impact factor: 2.078

Review 5.  Angina and myocardial infarction with normal coronary arteries.

Authors:  M E Bourke; D L Patterson
Journal:  Postgrad Med J       Date:  1991-01       Impact factor: 2.401

Review 6.  Acute coronary syndromes without coronary plaque rupture.

Authors:  Siddak S Kanwar; Gregg W Stone; Mandeep Singh; Renu Virmani; Jeffrey Olin; Takashi Akasaka; Jagat Narula
Journal:  Nat Rev Cardiol       Date:  2016-02-25       Impact factor: 32.419

Review 7.  Provocative testing for coronary reactivity and spasm.

Authors:  Melody Zaya; Puja K Mehta; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2013-11-06       Impact factor: 24.094

Review 8.  Overview of the Acetylcholine Spasm Provocation Test.

Authors:  Shozo Sueda; Hiroaki Kohno; Takaaki Ochi; Tadao Uraoka
Journal:  Clin Cardiol       Date:  2015-07-14       Impact factor: 2.882

9.  Mechanisms of ergonovine-induced hyperconstriction of coronary artery after x-ray irradiation in pigs.

Authors:  S Egashira; W Mitsuoka; H Tagawa; T Kuga; H Tomoike; M Nakamura; A Takeshita
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

10.  Reperfusion after acute coronary occlusion in dogs impairs endothelium-dependent relaxation to acetylcholine and augments contractile reactivity in vitro.

Authors:  K M VanBenthuysen; I F McMurtry; L D Horwitz
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.